Boston Scientific CorporationBSX
NYSE • Healthcare
$61.79
P/E
31.86
PEG
0.01
FCF Yield
—
Rev Growth YoY
+1988.0% YoY
Gross Margin
6901.0%
Health Score
6/10
D/E Ratio
0.47
Confidence
LOW
Business Snapshot
Boston Scientific Corporation is a leading global manufacturer of minimally invasive medical devices, operating across cardiology, electrophysiology, endoscopy, urology, and neuromodulation markets. The company sells its products to hospitals, clinics, and healthcare providers worldwide, competing in the large-cap segment of the Medical Devices industry. Based on available valuation ratios — including a P/E of 31.86x and a Price/Sales of 4.54x — BSX is consistent with a large-cap enterprise, though a precise market capitalisation figure is not available for this analysis.
Financial Health
**Score: 6/10** BSX presents a mixed but broadly stable financial picture. The debt/equity ratio of 0.47x is conservative and well within manageable territory, suggesting the balance sheet is not under stress...
Risk Assessment
- **DATA INTEGRITY:** Revenue growth of 1,988% YoY, gross margins of 6,901%, and net margins of 1,444% are statistically implausible for a mature medical device company and suggest corrupted or misadjusted data inputs — distorting nearly every derived metric. - **VALUATION:** P/E of 31.86x sits approximately 27% above the sector average of 25x, leaving limited margin of safety if growth normalises. - **TECHNICALS:** A confirmed death cross (50-day MA crossing below 200-day MA) is a bearish trend signal, and the MACD is also bearish; the current price of $61.79 is 43.6% below the 52-week high of $109.50. - **CASH FLOW:** Free cash flow data is unavailable, preventing any assessment of cash generation quality — a critical metric for capital-intensive device companies and DCF-based valuation. - **MISSING FUNDAMENTALS:** TTM Revenue, TTM Net Income, and DCF fair value are all absent from this payload, leaving the investment case without several core analytical pillars. ---...